Welcome to MOLOGEN AG

Our research - for you. That means, we conduct research to develop highly effective drugs with few side effects and excellent tolerability. Our main focus is on oncology and severe infectious diseases.

We use latest expertise from the fields of molecular medicine and immunology to enable the human immune system to fight the disease or disease pathogen itself - an approach that we are promoting with great conviction.

Using our own, patent-protected technology platforms, we are able to produce highly effective and extremely well-tolerated drugs against diseases with high unmet medical need. 

The biotechnology company MOLOGEN AG presented a poster on the clinical trial IMPALA with the cancer immunotherapy MGN1703 at the ESMO 17th World Congress on Gastrointestinal Cancer (WCGI) in Barcelona (July 1-4, 2015). The poster was titled "Immunomodulatory switch maintenance therapy to improve overall survival in metastatic colorectal... [more]

Today, the chairman of the supervisory board of MOLOGEN AG (ISIN DE0006637200/WKN 663720), Mr Oliver Krautscheid, informed the company that he will resign from his office as member and chairman of the supervisory board with effect as of the termination of the ordinary general meeting in 2015. At the same time, the supervisory board resolved... [more]

Interim Report 1st Quarter 2015

Download PDF (0,4 MB)

Annual Report 2014

Download PDF (0,4 MB)

Breakdown of phone system

At the moment you can only reach us by calling +49 03 841788-0 or via E-Mail.